Moreover, applying negative galectin-3 mutants—NH(2)-terminally truncated form of Gal-3 (galectin-3C)—resulted in reducing metastases, tumor volumes and weights in primary tumors in an orthotopic nude mouse model of human breast cancer [135]. This evidence concerns the gene LGALS3 and neoplasm.